dichlororibofuranosylbenzimidazole has been researched along with Carcinoma, Ehrlich Tumor in 1 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
Carcinoma, Ehrlich Tumor: A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Riedinger, HJ | 1 |
| Gekeler, V | 1 |
| Probst, H | 1 |
1 other study available for dichlororibofuranosylbenzimidazole and Carcinoma, Ehrlich Tumor
| Article | Year |
|---|---|
Reversible shutdown of replicon initiation by transient hypoxia in Ehrlich ascites cells. Dependence of initiation on short-lived protein.
Topics: Animals; Autoradiography; Carcinoma, Ehrlich Tumor; Cell Hypoxia; Cyclins; Cycloheximide; Dichlorori | 1992 |